{"entity":{"id":"nct07005570","kind":"trial","name":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS","aka":[],"tldr":"A phase 2 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by Dechang Diao, now recruiting.","summary":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK） is a phase 2, randomised interventional study registered as NCT07005570 by Dechang Diao, with a registry enrolment figure of 86 participants, started 2025-05-01 and due to reach its primary completion in 2027-07-01. Interventions recorded: Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab; Short-course radiotherapy followed by sequential chemotherapy. Conditions listed: pMMR/MSS Locally Advanced Rectal Cancer. Primary outcome: Complete Response (CR) Rate; Adverse events. Colorectal eligibility wording from the registry: \"Histologically confirmed rectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07005570","url":"https://clinicaltrials.gov/study/NCT07005570"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07005570","phase":"2","setting":"Short-Course Radiotherapy Followed by Sequential Chemotherapy Combined With PD-1 Monoclonal Antibody and Bevacizumab Versus Short-Course Radiotherapy Followed by Sequential Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer","sponsor":"Dechang Diao","enrolled":86,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07005570/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}